Avvio Medical to Present Clinical Trial Results at the 2025 American Urological Association Annual Meeting
Moderated Interactive Poster Presentation
Presenter: Wesley Mayer, MD
Title: A Prospective, Multi-Center, Randomized, Placebo-Controlled Clinical Trial Evaluating the Safety and Efficacy of Ureteroscopic Laser Lithotripsy With and Without Acoustic Enhancer Microbubble Cavitation for the Treatment of Urolithiasis
Session: IP08-22
Date/Time: April 26, 3:30–5:30 PM
Location: Room Marco Polo 701
This clinical presentation adds to the growing body of evidence supporting Avvio's proprietary technology. Avvio Medical is also looking to initiate its forthcoming pivotal clinical trial evaluating the safety and effectiveness of Acoustic Enhancer Microbubbles delivered with its breakthrough Enhanced Lithotripsy System (ELS).
'There is a clear need for improved and novel strategies in stone management,' said Paul Molloy, President and Chief Executive Officer of Avvio Medical. 'We are thrilled to advance our clinical research with our patented microbubbles and the Enhanced Lithotripsy System—a revolutionary approach to treating urinary stones.'
For more information, go to avviomed.com or visit Suite 115 at AUA and schedule a demo of the technology.
About the Enhanced Lithotripsy System (ELS)
The AVVIO ELS introduces microbubble enhanced acoustic cavitation lithotripsy that enables kidney stone treatments to move out of the traditional operating room and into more accessible outpatient and office-based settings. The system provides a single, minimally invasive therapy suitable for Ambulatory Surgery Centers (ASCs) and cystoscopy suites, without requiring general anesthesia, fluoroscopy, or costly capital equipment. This innovation offers compelling clinical and economic advantages for both patients and providers.
About Avvio Medical
Avvio Medical is a privately held medical technology company based in San Francisco and dedicated to transforming the treatment of urinary stones. Its breakthrough platform is designed to improve patient experience, reduce healthcare costs, and expand access to care by offering a fast, minimally invasive solution suitable for a wide range of clinical settings. The company's system eliminates the routine need for general anesthesia or X-ray imaging, streamlining the treatment pathway for both patients and healthcare professionals.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
14 minutes ago
- Business Wire
Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference
HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) ('Zura Bio' or the 'Company'), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today announced that its senior leadership team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 4, 2025, at 2:45 PM ET in New York, NY. The Company will also conduct one-on-one investor meetings on the same day. A live webcast of the presentation will be available in the Investors section of the Company's website under News & Events. A replay will remain archived for at least 30 days. ABOUT ZURA BIO Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs. The Company's pipeline includes dual-pathway product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura Bio's lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies in adults, including TibuSURE for systemic sclerosis and TibuSHIELD for hidradenitis suppurativa. Additional product candidates, crebankitug (ZB-168) and torudokimab (ZB-880), have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions. For more information, please visit
Business Wire
44 minutes ago
- Business Wire
Bonerge Unveils StanYouth® CR3: A Revolutionary Anti-Aging Complex Merging TCM Wisdom and Cellular Science
NEW YORK--(BUSINESS WIRE)--Bonerge has unveiled its revolutionary anti-aging Product, StanYouth® CR3, a patented formula that bridges Traditional Chinese Medicine (TCM) philosophy with cutting-edge cellular science. Inspired by TCM's "Senolytic-Repair-Chi" theory, this synergistic complex targets aging at the cellular level, offering a multi-dimensional solution to combat senescence. Rooted in the TCM principle of "treating disease before it arises," StanYouth® CR3 operates through a three-stage mechanism mirroring "Senolytic-Repair-Chi." Its core ingredients—Fisetin (FIS), Urolithin A (UA), and L-Ergothioneine (EGT)—work in harmony to address aging at its source. Fisetin: The Senolytic Purifier As a natural flavonoid with superior cell membrane penetration, Fisetin selectively eliminates senescent cells—dysfunctional cells that linger and secrete pro-inflammatory senescence-associated secretory phenotypes (SASP), accelerating tissue aging. It not only clears existing senescent cells but also reduces new ones, cutting inflammatory factor production at the source to purify the cellular environment [1,2]. Urolithin A: The Homeostasis Restorer Cellular aging thrives on disrupted metabolic and circadian rhythms, which worsen inflammation and weaken clock gene function. Urolithin A repairs this balance by regulating core clock genes (e.g., CLOCK, PER2) critical for gut metabolism and boosting the expression amplitude of BMAL1 in senescent cells, restoring their circadian rhythms and metabolic homeostasis [3,4]. L-Ergothioneine: The Defense Enhancer Environmental stress and metabolism generate reactive oxygen/nitrogen species (ROS/RNS) that damage DNA and deplete vitality. L-Ergothioneine, via its unique OCTN-1 transporter, accumulates in high-oxidative-stress areas like mitochondria and nuclei, neutralizing free radicals in real time. It also upregulates endogenous antioxidant enzymes, strengthening cellular resilience and nourishing vital energy ("Chi")[5,6]. Synergistic Power: A Closed-Loop Mechanism Together, they form a "Senolytic-Repair-Chi" cycle. Fisetin clears senescent burdens, creating a healthy foundation; Urolithin A restores rhythms and metabolism; L-Ergothioneine fortifies defenses, preventing further damage—each amplifying the others' effects. Cellular Experiments Validate Superiority Tests on human dermal fibroblasts revealed striking results: StanYouth® CR3 cleared up to 80% of senescent cells, doubling Fisetin's solo performance. It suppressed senescence markers p16 and p21 to near-normal levels, outperforming single ingredients. Critically, it reduced pro-inflammatory IL-6, IL-8, and fibrosis-driving IL-11 to baseline, blocking the "senescence-inflammation-fibrosis" cycle. It also inhibited UVB-induced ROS and boosted cell migration —key for repair—far better than individual components. Clinical Trial Confirms Efficacy A 56-day human trial showed StanYouth® CR3 outperformed standalone L-Ergothioneine: skin firmness (F4) rose 16.3%, under-eye wrinkles fell 11.28%, brightness (L*) increased 1.4%, and fairness (ITA) improved 6.10%, skin barrier repair (TEWL reduction) reached 18.18%. "StanYouth® CR3 is more than an anti-aging formula— it's a bridge between ancient TCM wisdom and modern cellular science," noted a Bonerge product manager. By translating the holistic "Senolytic-Repair-Chi" principle into a precise, synergistic cellular strategy, it delivers proven efficacy from laboratory to real-world application. As Bonerge continues to explore its potential beyond skin health, StanYouth® CR3 marks a new era in evidence-based anti-aging, where tradition and innovation converge to redefine vitality. References [1] Kento Takaya, et al. Biogerontology. 2024 Feb;25(1):161-175. [2] Li Zhang, Xiang Tong, et al. Front Pharmacol. 2020 Dec 14:11:553690. [3] Yao Du, Xinyue Chen et al. Nutrients 2024, 16, 2263. [4] Rassul Kuatov, Jiro Takano et 2024 Dec 25;17(1):20. [5] Hui-Min Liu, Wei Tang, et al. Molecules. 2023 Feb 8;28(4):1648. [6] Yasaaswini Apparoo, Chia Wei Phan, et al. Exp Gerontol. 2022 Dec:170:111982.
Business Wire
14 hours ago
- Business Wire
Small Medical Practices Are Sitting Ducks for Healthcare Cybercrime
SAN FRANCISCO--(BUSINESS WIRE)--Over 90% of U.S. healthcare providers operate as small organizations, yet a new Paubox report titled "What small healthcare practices get wrong about HIPAA and email security" reveals these practices are unknowingly exposing themselves to cyber attacks and federal compliance violations. 98% of small healthcare organizations falsely believe they're HIPAA compliant Share The study of 214 healthcare IT leaders and practice managers at organizations with fewer than 250 employees found that nearly all small practices (98%) claim their platforms "encrypt emails by default"—but most are using common tools like Microsoft 365 or Google Workspace that often fail to provide actual protection. "Nearly half of healthcare email breaches stem from Microsoft 365 alone," the survey found. The problem is that encryption may drop if a recipient's server doesn't support modern protocols, often without any alert to the sender—leaving protected health information completely exposed. The confidence crisis More than 80% of small practices expressed confidence in their current HIPAA compliance posture, but the reality is far different. The survey found widespread misconceptions that are creating massive compliance gaps: 83% believe patient consent removes the need for encryption—a costly misunderstanding. Federal regulations still require "appropriate safeguards" under the HIPAA Security Rule, even when patients agree to electronic communication. Getting a patient's okay to email doesn't eliminate the legal requirement for encryption and other protective measures. 64% believe patient portals are required for HIPAA compliance—yet the regulations say the opposite. HIPAA explicitly gives patients the right to request communication "by alternative means or at alternative locations, if reasonable." Portals are just one option among many, including secure direct email when proper safeguards are in place. 20% don't utilize any form of email archiving or audit trail—leaving one in five practices unable to investigate incidents after they happen or prove compliance during federal audits. These misconceptions create compliance violations that practices don't even realize exist, with healthcare providers unknowingly breaking federal law while genuinely believing they're following the rules. Cybercriminals target the vulnerable Phishing attacks—the leading cause of healthcare breaches—now account for over 70% of healthcare data breaches as of 2024. Small practices are prime targets because they typically lack dedicated security staff, formal training programs, or technical defenses. The survey found that 43% of small healthcare organizations reported experiencing a phishing or spoofing incident in the past year. Meanwhile, about 50% of these organizations lack anti-phishing controls beyond default spam filters, and nearly 99% have not implemented secure email transfer protocols. "Phishing attacks have evolved—they're faster, smarter, and relentless," noted Paubox CEO, Hoala Greevy. "It's not about one-off scams anymore; it's deception at scale." Beyond the breach When breaches occur, small practices face the same serious consequences as large health systems. Recent examples from the past year include: Solara Medical : $9.76 million class-action settlement following a phishing attack : $9.76 million class-action settlement following a phishing attack Sunrise Community Health : Email compromise affecting 54,000+ patients : Email compromise affecting 54,000+ patients Salud Family Health: Phishing attack exposing 80,000+ records Even smaller penalties come with major operational costs. Agape Health, a North Carolina clinic, paid $25,000 for emailing protected health information unencrypted to the wrong recipient, while Vision Upright MRI faced a $5,000 fine plus two years of federal monitoring after a server breach exposed over 21,000 individuals' medical imaging records. In 2025, healthcare breaches took an average of 224 days to detect and another 84 days to contain—over 10 months total. Without proper audit trails, many small organizations lack the systems to spot breaches until it's too late. Stretched thin and vulnerable The survey found that small healthcare practices are operating under dangerous constraints that create the perfect storm for security failures: One-third report not having enough time for compliance tasks—meaning critical security measures get pushed aside during busy patient care schedules. The same number have no clear policies or procedures in place, leaving staff to make up security protocols on the fly. Only half have phishing or spoofing protection enabled, despite facing the same sophisticated attacks that target major health systems. Meanwhile, the average small healthcare employee has access to more than 5,500 sensitive files—creating massive exposure when those unprotected phishing emails inevitably get through. This combination of time pressure, unclear guidance, and broad data access means a single clicked link can expose thousands of patient records. It's a vulnerability that cybercriminals are increasingly exploiting. What HIPAA investigators look for When HHS investigators arrive after a breach, they look for specific documentation that most small practices can't provide: Proof that protected health information was encrypted in transit—not just that platforms "support" encryption Audit logs showing who sent what to whom and whether it was properly protected Evidence of risk assessments documenting understood vulnerabilities Incident response procedures for when things go wrong "Every organization, no matter the size, is required to comply with the HIPAA Security Rule," emphasized Melanie Fontes Rainer, Director of the HHS Office for Civil Rights. "Risk assessments are not optional—they're foundational." The path forward With federal enforcement ramping up and cybercriminals increasingly targeting small practices, the window for voluntary compliance is closing fast. The practices that are getting ahead of this crisis share a common strategy: they've stopped relying on overworked staff to make perfect security decisions every time. Instead, they're implementing systems that encrypt every message automatically, maintain detailed audit trails without extra effort, and block phishing attacks before employees ever see them. "The cost of compliance is far less than the cost of a breach," the survey noted—and recent settlements prove it. At $25,000 to $9.76 million per incident, even "small" violations can devastate a practice's finances and reputation. For the 90% of healthcare providers operating as small organizations, the math is simple: invest in automated protection now, or face the much higher costs of breach response, federal penalties, and lost patient trust later. The choice is becoming less optional every day. The complete report, "What small healthcare practices get wrong about HIPAA and email security," is available for download at About Paubox Paubox is a leader in HIPAA compliant communication and marketing solutions for healthcare organizations. According to G2 rankings, Paubox leads the industry for Best Secure Email Gateway, Email Security, HIPAA Compliant Messaging Software, and Email Encryption solution, and is the only HIPAA compliant email company listed on G2's 2025 Best Healthcare Software Products. Paubox solutions include Paubox Email Suite, Paubox Marketing, Paubox Email API, Paubox Forms, and Paubox Texting. Launched in 2015, Paubox is trusted by over 7,000 healthcare organizations, including Cost Plus Drugs, Covenant Health, Devry University, and SimonMed Imaging.
